Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | CDC14B | O60729 | 1/20 | 0.31 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31495900 | 0.77 | LOXL2 (0.35) | LOXL2CDC14BCDC14A | |
| SCHEMBL31107785 | 0.76 | LOXL2 (0.36) | LOXL2CDC14BCDC14A | |
| SCHEMBL31495802 | 0.74 | LOXL2 (0.30) | LOXL2 | |
| SCHEMBL31107772 | 0.70 | LOXL2 (0.39) | LOXL2 | |
| SCHEMBL31107723 | 0.70 | LOXL2 (0.39) | LOXL2 | |
| SCHEMBL31566382 | 0.68 | IDO1 (0.30) | — | |
| SCHEMBL29208181 | 0.68 | LOXL2 (0.34) | LOXL2 | |
| SCHEMBL12093432 | 0.68 | LOXL2 (0.47) | LOXL2CDC14BCDC14A | |
| SCHEMBL29450783 | 0.68 | LOXL2 (0.47) | LOXL2CDC14BCDC14A | |
| SCHEMBL31495806 | 0.67 | ENPP3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085725-A1 | METHODS FOR TREATING A P53-ASSOCIATED CANCER | SCORPION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250120961-A1 | P53 MODULATORS | NESTED THERAPEUTICS INC (US) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120961-A1 | P53 MODULATORS | TP53, TP53BP1, MDM2 | LOXL2 4365/4885CDC14B 1643/4885CDC14A 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.